Inil for integration?
The newly discovered Inil cellular protein binds HIV-1 integrase and is part of a protein complex thought to alter nucleosomal structure; such alterations may influence the selection of sites for HIV-1 DNA integration.
Many gene therapy protocols use retroviruses to deliver correCtive genes to diseased cells, primarily because retroviral infection culminates in the covalent insertion of reverse-transcribed retroviral DNA into host cell chromosomes. This DNA integration ensures that the therapeutic gene will be maintained indefinitely in the target cells. But retroviral DNA integration can also adversely influence host genes; examples of potentially harmful effects include the insertional inactivation of a host gene, inappropriate transcriptional activation of a nearby gene, and the creation of a novel fusion protein by joining a viral exon to a nearby host exon [1] . It is well-documented that such lesions can lead to problems as severe as transformation of the host cell. At present, there is no way to control the site of retroviral integration in vivo, so if large numbers of cells are infected during gene therapy, the chance of a harmful integration event occurring becomes uncomfortably high. Recently, several reports have indicated that it may be possible to control integration-site selection in vivo and so to restrict integration to 'safe' sites in the host DNA.
In one of these studies, Kalpana et al. [2] used the yeast two-hybrid genetic-interaction screening method to search for cellular proteins that might participate in retroviral DNA integration. As 'bait' they used the HIV-1 integrase protein, which forms the initial covalent connection between the retroviral cDNA and the host DNA. Their screen yielded a cDNA clone encoding a protein that binds specifically to integrase both in vivo and in vitro. The integrase-binding protein, designated Inil (integrase-interacting protein 1), had not been described previously, but displays a high degree of sequence similarity to the yeast protein Snf5, a factor that is implicated in the transcriptional activation of a number of genes.
To ask what function Inil might serve during HIV-1 integration, Kalpana et al. [2] tested the effect of adding purified Inil-glutathione-S-transferase fusion protein to an in vitro assay for the DNA-joining activity of HIV-1 integrase. They found that, at certain concentrations, the Inil fusion protein increased the efficiency of integration. This effect was also seen using cytoplasmic extracts enriched for Inil, but not with extracts that had been depleted of Inil by affinity chromatography, suggesting that the cellular Inil protein functions in a similar way to the fusion protein that was produced in bacteria. However, other small nucleic-acid-binding proteins that are not thought to bind specifically to the integration machinery can also boost integration efficiency in this assay [3] , so the results in vitro must be interpreted with caution. Nevertheless, the observation of these activities, together with the sequence similarity to yeast Snf5, makes a provocative case that Inil has a role in HIV-1 DNA integration.
If Inil binds to DNA, it might serve as a protein bridge that moors the retroviral integration machinery to the host DNA, possibly directing integration to desired sites ( Fig. la) , as suggested by Kalpana and Goff [2] . Indeed, such a mechanism has a precedent in the behavior of the yeast retrotransposon Ty3, which transposes by reverse transcription of Ty3 mRNA and integration of the resulting cDNA at a different site in the same cell. These steps are performed by Ty3-encoded reverse transcriptase and integrase proteins that are homologous to those of retroviruses. The Ty3 life-cycle is thus biochemically similar to that of a retrovirus, except that it does not have an extracellular phase. Unlike retroviruses, however, Ty3 integrates at specific sites, always within five base pairs of the transcriptional start site of genes transcribed by RNA polymerase III. As DNA insertion upstream of polymerase III transcription units has little impact on the health of the cell, Ty3 probably evolved this mechanism to avoid insertional mutagenesis of genes that are necessary for the survival of its host. Genetic studies have shown that efficient Ty3 targets require intact binding sites for the basal transcription factors TFIIIB and TFIIIC. Transcription itself is not required, however, suggesting that tethering of the Ty3 integration machinery to the polymerase III transcription complex mediates selective integration [4] .
The findings with Ty3 indicated that artificially tethering retroviral integration machinery to a specific DNA sequence might force the retroviral DNA to integrate at a chosen site, and a recent study confirmed this prediction in vitro [5] . The gene encoding HIV-1 integrase (IN) was fused to DNA encoding the sequence-specific DNAbinding domain of the bacteriophage repressor (R). The XR-IN-encoded fusion protein directed integration in vitro selectively into DNA fragments containing operators (binding sites for the repressor protein). An analysis of the integration sites that were used showed that integration occurred predominately into sequences within 100 base-pairs of the operators and on the same face of the DNA helix as the operators; little or no integration took place in the operator sites themselves. These results suggested that the R protein domain bound operator sequences, thereby tethering the integrase protein domain to the operators and promoting integration into adjacent sequences. Thus, XR-IN achieved the goal of directing selective integration. Ty3 and XR-IN each provide an example of how integration can be directed near specific DNA sites by tethering, and the binding of the HIV-1 integrase protein domain to the Inil protein could be yet another example. Although XR-IN-mediated integration was selective, the sites used were distributed over longer stretches of DNA than those used by. Ty3. It is not known why Ty3 displays such remarkable specificity relative to XR-IN, but possible explanations include different arrangements of integrase monomers, the involvement of additional proteins, and the presence in Ty3 targets of unusual DNA structures, such as kinks or other distortions.
The efficiency of retroviral DNA integration depends strongly on the structure of the target DNA. For example, a naked DNA molecule with an intrinsic curve is a better integration target than a naked DNA molecule with a rigid or flexible structure, and all DNAs so far studied become more efficient integration targets when incorporated into nucleosomes [6-8]. The latter phenomenon is attributable to the change in DNA structure that occurs when DNA is wrapped around a histone octamer: in order to maintain contact with the histones, the DNA helical axis changes direction sharply at two sites per nucleosome, thereby introducing kinks into the DNA [9]. Integration is highly favored at these kinked sites [7] , and indeed at other sites of DNA distortion [10] .
Inil might also function as more than a simple tether during HIV-1 DNA integration. The apparent yeast homolog of Inil, Snf5, is one of at least five proteins in the Swi/ Snf complex. Genetic studies in yeast have implicated this complex as being important for transcriptional activation of a large number of genes (for a recent review, see [11] ). Potentially homologous complexes are also found in human cells, and Inil is probably a member of this complex, as the Inil integrase-stimulating activity can be removed from extracts using an antibody against another component of the complex. Purified Swi/Snf complexes from yeast and human cells were recently reported to alter the structure of nucleosomal DNA in vitro so as to promote the binding of sequence-specific transcriptional control proteins [12] [13] [14] , a function that may begin to explain the ability of Swi/Snf proteins to influence the transcription of a diverse set of genes in vivo. It is not yet understood how Swi/Snf complexes alter the nucleosomal structure, but the remodeling that does occur is accompanied by dramatic changes in DNA topology [13] that might promote integration. But there seems to be a paradox: packaging DNA into nucleosomes makes it a better integration target, yet the integration machinery apparently interacts with a component of the Swi/Snf complex, which is thought to disrupt nucleosomes.
How can these observations be reconciled? Kalpana and Goff [2] suggest that contact between Inil and integrase may stimulate the DNA-joining activity of the integrase, consistent with the observed stimulation of integration by Inil in vitro (Fig. lb) . If nucleosomes modified by the Swi/Snf complex really are less attractive integration targets than unmodified nucleosomes, the stimulation of integrase activity by Inil might nevertheless result in a net increase in integration. However, integration into nucleosomes altered by the Swi/Snf complex has not been studied, so it is also possible that nucleosomal DNA becomes an even better target under the influence of the Swi/Snf complex (Fig. c) . Perhaps the nucleosome alterations that are generated by the Swi/Snf complex serve to unfold higher-order chromatin structures (for example, 30 nm chromatin fibers) and so to make nucleosomal targets more accessible. As purified human Swi/Snf complexes and purified HIV-1 preintegration complexes are now available, these possibilities can be tested.
The discovery that the HIV-1 integration machinery can bind to a cellular protein provides a new avenue for the study of target-site selection during HIV-1 integration. Together with recent advances towards directing HIV-1 integration to specific DNA sequences in vitro and in understanding how Ty3 integrates at specific positions in vivo, this finding offers hope that we may be able to influence integration-site selection during retroviral infection. Ultimately, retroviral vectors might be designed to integrate at predetermined DNA sites in vivo, making them safer for the delivery of DNA sequences in gene therapy. Perhaps such vectors could also be designed for insertional inactivation of a harmful gene, such as an activated oncogene, bringing a new degree of flexibility to human gene manipulation. 
